

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
20 April 2000 (20.04.2000)


PCT

(10) International Publication Number  
**WO 00/21437 A3**

- (51) International Patent Classification?: **A61B 5/00** (74) Agents: **WHEELOCK, E., Thomas et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).**
- (21) International Application Number: **PCT/US99/23823**
- (22) International Filing Date: **12 October 1999 (12.10.1999)** (81) Designated States (*national*): **AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW.**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
**60/103,883 13 October 1998 (13.10.1998) US** (84) Designated States (*regional*): **ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).**
- (71) Applicant (*for all designated States except US*): **MEDOPTIX, INC. [US/US]; 10011 N. Foothill Blvd., Suite 107, Cupertino, CA 95014 (US).**
- (72) Inventors; and  
(75) Inventors/Applicants (*for US only*): **BERMAN, Herbert, L. [US/US]; 12680 Viscaio Road, Los Altos Hills, CA 94022 (US). ROE, Jeffrey, N. [US/US]; 3212 Veracruz Drive, San Ramon, CA 94583 (US).**
- Published:  
— *with international search report*
- (88) Date of publication of the international search report:  
**19 July 2001**

[Continued on next page]

(54) Title: **INFRARED ATR GLUCOSE MEASUREMENT SYSTEM**



(57) Abstract: This involves a non-invasive glucose measurement device and a process for determining blood glucose level in the human body using the device. In typical operation, the glucose measurement device is self-normalizing in that it does not employ an independent reference sample in its operation. The device uses attenuated total reflection (ATR) infrared spectroscopy. Preferably, the device is used on a fingertip and compares two specific regions of a measured infrared spectrum to determine the blood glucose level of the user. Clearly, this device is especially suitable for monitoring glucose levels in the human body, and is especially beneficial to users having diabetes mellitus. The device and procedure may be used for other analyte materials which exhibit unique mid-IR signatures of the type described herein and that are found in appropriate regions of the outer skin.

WO 00/21437 A3



*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/23823

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61B5/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 169 676 A (KAISER) 2 October 1979 (1979-10-02) cited in the application	1-3, 7, 8, 10, 12, 13, 16, 18 19, 25, 28, 34, 36, 37, 40, 46, 48
X	the whole document	
A	WO 97 29368 A (SHELL) 14 August 1997 (1997-08-14)	1, 9-11, 16-19, 26, 27, 29, 34-41, 46-48
	the whole document	
	--- -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

20 April 2000

Date of mailing of the international search report

11. 05. 2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Lemercier, D

# INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/US 99/23823

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>US 4 427 889 A (MÜLLER) 24 January 1984 (1984-01-24)</p> <p>column 2, line 50 -column 3, line 29 column 5, line 55 -column 7, line 51</p> <p>---</p>	<p>1-3, 7-15, 19, 26-28, 37, 41</p>
A	<p>US 4 538 618 A (ROSENBERG &amp; AL) 3 September 1985 (1985-09-03) column 2, line 22 - line 34</p> <p>---</p>	<p>1, 4-6, 19-22</p>
A	<p>US 5 470 323 A (SMITH &amp; AL.) 28 November 1995 (1995-11-28) column 3, line 63 -column 4, line 34</p> <p>---</p>	<p>49</p>
A	<p>EP 0 329 361 A (SUNTORY) 23 August 1989 (1989-08-23) page 6, line 56 -page 7, line 31</p> <p>---</p>	<p>49-51</p>
A	<p>US 4 710 231 A (BATEMAN) 1 December 1987 (1987-12-01) column 3, line 21 - line 23</p> <p>---</p>	<p>49, 52</p>
A	<p>WO 96 19180 A (MAYBELLINE) 27 June 1996 (1996-06-27) page 14, line 13 - line 16</p> <p>-----</p>	<p>49, 50, 53</p>

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 99/23823

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-48

Method and device for measuring glucose by infrared attenuated total reflectance

2. Claims: 49-53

Cleaning kit

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/23823

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4169676 A	02-10-1979	DE 2606991 A BE 851606 A CA 1084300 A CH 612271 A FR 2341866 A GB 1531375 A IT 1071579 B JP 52102094 A LU 76810 A NL 7701778 A SE 7701901 A	25-08-1977 16-06-1977 26-08-1980 13-07-1979 16-09-1977 08-11-1978 10-04-1985 26-08-1977 06-07-1977 23-08-1977 21-08-1977
WO 9729368 A	14-08-1997	AU 1584797 A EP 0880698 A	28-08-1997 02-12-1998
US 4427889 A	24-01-1984	DE 2934190 A DE 3069635 D WO 8100622 A EP 0034156 A JP 56501174 T	19-03-1981 20-12-1984 05-03-1981 26-08-1981 20-08-1981
US 4538618 A	03-09-1985	IL 68115 A	31-03-1987
US 5470323 A	28-11-1995	US 5242433 A CA 2151122 A EP 0746377 A WO 9413354 A US 5460620 A	07-09-1993 23-06-1994 11-12-1996 23-06-1994 24-10-1995
EP 329361 A	23-08-1989	AT 131169 T AU 2969489 A CA 1335365 A DE 68924991 D DE 68924991 T ES 2080068 T JP 1304893 A JP 2865302 B US 5021406 A	15-12-1995 17-08-1989 25-04-1995 18-01-1996 11-07-1996 01-02-1996 08-12-1989 08-03-1999 04-06-1991
US 4710231 A	01-12-1987	AT 26465 T AU 2314384 A CA 1245645 A EP 0116389 A ES 528719 D ES 8602950 A FI 840055 A GB 2133796 A,B GR 79494 A JP 59162900 A NO 840038 A PT 77919 A,B	15-04-1987 12-07-1984 29-11-1988 22-08-1984 01-12-1985 16-03-1986 08-07-1984 01-08-1984 30-10-1984 13-09-1984 09-07-1984 01-02-1984
WO 9619180 A	27-06-1996	AU 4603096 A EP 0796077 A US 5876736 A	10-07-1996 24-09-1997 02-03-1999



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>7</sup> : <b>A61B 5/00</b></p>	<p><b>A2</b></p>	<p>(11) International Publication Number: <b>WO 00/21437</b></p> <p>(43) International Publication Date: <b>20 April 2000 (20.04.00)</b></p>
<p>(21) International Application Number: <b>PCT/US99/23823</b></p> <p>(22) International Filing Date: <b>12 October 1999 (12.10.99)</b></p> <p>(30) Priority Data: <b>60/103,883</b>      <b>13 October 1998 (13.10.98)</b>      <b>US</b></p> <p>(71)(72) Applicants and Inventors: <b>BERMAN, Herbert, L.</b> [US/US]; 12680 Viscaino Road, Los Altos Hills, CA 94022 (US). <b>ROE, Jeffrey, N.</b> [US/US]; 3212 Veracruz Drive, San Ramon, CA 94583 (US).</p> <p>(74) Agents: <b>WHEELOCK, E., Thomas et al.; Morrison &amp; Foerster LLP</b>, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i></p>
<p>(54) Title: <b>INFRARED ATR GLUCOSE MEASUREMENT SYSTEM</b></p> <div data-bbox="324 1113 1299 1680"> </div> <p>(57) Abstract</p> <p>This involves a non-invasive glucose measurement device and a process for determining blood glucose level in the human body using the device. In typical operation, the glucose measurement device is self-normalizing in that it does not employ an independent reference sample in its operation. The device uses attenuated total reflection (ATR) infrared spectroscopy. Preferably, the device is used on a fingertip and compares two specific regions of a measured infrared spectrum to determine the blood glucose level of the user. Clearly, this device is especially suitable for monitoring glucose levels in the human body, and is especially beneficial to users having diabetes mellitus. The device and procedure may be used for other analyte materials which exhibit unique mid-IR signatures of the type described herein and that are found in appropriate regions of the outer skin.</p>		



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## INFRARED ATR GLUCOSE MEASUREMENT SYSTEM

### Related Applications

5           This is a continuation-in-part of U.S. App. Ser. No. 60/103,883, to Berman and Roe, filed October 13, 1998.

### Field of the Invention

10           This invention involves a non-invasive glucose measurement device and a process for determining blood glucose level in the human body using the device. In typical operation, the glucose measurement device is self-normalizing in that it does not employ an independent reference sample in its operation. The inventive device uses attenuated total reflection (ATR) infrared spectroscopy. Preferably, the device is used on a fingertip and compares two specific regions of a measured infrared spectrum to determine the blood  
15           glucose level of the user. Clearly, this device is especially suitable for monitoring glucose levels in the human body, and is especially beneficial to users having diabetes mellitus. The device and procedure may be used for other materials which exhibit unique mid-IR signatures of the type described below and that are found in appropriate regions of the outer skin. A cleaning kit for preparation of the skin surface is also included.

20

### Background of the Invention

25           The American Diabetes Association reports that nearly 6% of the population in the United States, a group of 16 million people, has diabetes. The Association further reports that diabetes is the seventh leading cause of death in the United States, contributing to nearly 200,000 deaths per year. Diabetes is a chronic disease having no cure. The complications of the disease include blindness, kidney disease, nerve disease, and heart disease, perhaps with stroke. Diabetes is said to be the leading cause of new cases of blindness in individuals in the range of ages between 20 and 74; from 12,000-24,000 people per year lose their sight because of diabetes. Diabetes is the leading cause of end-  
30           stage renal disease, accounting for nearly 40% of new cases. Nearly 60-70% of people with diabetes have mild to severe forms of diabetic nerve damage which, in severe forms,

can lead to lower limb amputations. People with diabetes are 2-4 times more likely to have heart disease and to suffer strokes.

Diabetes is a disease in which the body does not produce or properly use insulin, a hormone needed to convert sugar, starches, and the like into energy. Although the cause of diabetes is not completely understood, genetics, environmental factors, and viral causes  
5 have been partially identified.

There are two major types of diabetes: Type I and Type II. Type I diabetes (formerly known as juvenile diabetes) is an autoimmune disease in which the body does not produce any insulin and most often occurs in young adults and children. People with Type  
10 I diabetes must take daily insulin injections to stay alive.

Type II diabetes is a metabolic disorder resulting from the body's inability to make enough, or properly to use, insulin. Type II diabetes accounts for 90-95% of diabetes. In the United States, Type II diabetes is nearing epidemic proportions, principally due to an increased number of older Americans and a greater prevalence of obesity and a sedentary  
15 lifestyle.

Insulin, in simple terms, is the hormone that unlocks the cells of the body, allowing glucose to enter those cells and feed them. Since, in diabetics, glucose cannot enter the cells, the glucose builds up in the blood and the body's cells literally starve to death.

Diabetics having Type I diabetes typically are required to self-administer insulin using, e.g., a syringe or a pin with needle and cartridge. Continuous subcutaneous insulin  
20 infusion via implanted pumps is also available. Insulin itself is typically obtained from pork pancreas or is made chemically identical to human insulin by recombinant DNA technology or by chemical modification of pork insulin. Although there are a variety of different insulins for rapid-, short-, intermediate-, and long-acting forms that may be used  
25 variously, separately or mixed in the same syringe, use of insulin for treatment of diabetes is not to be ignored.

It is highly recommended by the medical profession that insulin-using patients practice self-monitoring of blood glucose (SMBG). Based upon the level of glucose in the blood, individuals may make insulin dosage adjustments before injection. Adjustments are  
30 necessary since blood glucose levels vary day to day for a variety of reasons, e.g., exercise, stress, rates of food absorption, types of food, hormonal changes (pregnancy, puberty, etc.) and the like. Despite the importance of SMBG, several studies have found that the

proportion of individuals who self-monitor at least once a day significantly declines with age. This decrease is likely due simply to the fact that the typical, most widely used, method of SMBG involves obtaining blood from a finger stick. Many patients consider obtaining blood to be significantly more painful than the self-administration of insulin.

5           There is a desire for a less invasive method of glucose measurement. Methods exist or are being developed for a minimally invasive glucose monitoring, which use body fluids other than blood (e.g., sweat or saliva), subcutaneous tissue, or blood measured less invasively. Sweat and saliva are relatively easy to obtain, but their glucose concentration appears to lag in time significantly behind that of blood glucose. Measures to increase  
10       sweating have been developed and seem to increase the timeliness of the sweat glucose measurement, however.

          Subcutaneous glucose measurements seem to lag only a few minutes behind directly measured blood glucose and may actually be a better measurement of the critical values of glucose concentrations in the brain, muscle, and in other tissue. Glucose may be  
15       measured by non-invasive or minimally-invasive techniques, such as those making the skin or mucous membranes permeable to glucose or those placing a reporter molecule in the subcutaneous tissue. Needle-type sensors have been improved in accuracy, size, and stability and may be placed in the subcutaneous tissue or peripheral veins to monitor blood glucose with small instruments. See, "*An Overview of Minimally Invasive Technologies*",  
20       Clin. Chem. 1992 Sep.; 38(9):1596-1600.

          Truly simple, non-invasive methods of measuring glucose are not commercially available.

          U.S. Patent No. 4,169,676 to Kaiser, shows a method for the use of ATR glucose measurement by placing the ATR plate directly against the skin and especially against the  
25       tongue. The procedure and device shown there uses a laser and determines the content of glucose in a specific living tissue sample by comparing the IR absorption of the measured material against the absorption of IR in a control solution by use of a reference prism. See, column 5, lines 31 et seq.

          None of the cited prior art suggests the device and method of using this device  
30       described and claimed below.

### SUMMARY OF THE INVENTION

This invention is a glucose level measurement device utilizing IR-ATR spectroscopy and a method of using the device. The inventive device itself preferably made  
5 up of four parts:

- a.) an IR source for emitting an IR beam into the ATR plate,
- b.) the ATR plate against which the sampled human skin surface is pressed,

and

- c.) at least two IR sensors for simultaneously measuring absorbance of two  
10 specific regions of the IR spectrum, i.e., a "referencing wavelength" and a "measuring wavelength." The IR source must emit IR radiation at least in the region of the referencing wavelength and the measuring wavelength. For glucose, the referencing wavelength is between about 8.25 micrometers and about 8.75 micrometers and the measuring wavelength is between about 9.50 micrometers and about 10.00 micrometers. The IR  
15 sources may be broadband IR sources, non-laser sources, or two or more selected wavelength lasers.

Other analyte materials which have both referencing wavelengths and measuring wavelengths as are described in more detail below and that are found in the outer regions of the skin may be measured using the inventive devices and procedures described herein.

- 20 The ATR plate is configured to permit multiple internal reflections, perhaps 3-15 internal reflections, against said measurement surface prior to measurement by the IR sensors. Typically the IR beam emitted from the ATR plate is split for the IR sensors using a beam splitter or equivalent optical device. Once the split beams are measured by the IR sensors, the resulting signals are then transformed using analog comparators or digital  
25 computers into readable or displayable values.

It is usually important that the device have some accommodation for holding the body part against the ATR plate, preferably at some value which is constant and above a selected minimum pressure.

- 30 The method for determining the blood glucose level, using the glucose measurement device, comprises the steps of.

- a.) contacting a selected skin surface with the ATR plate,

b.) irradiating that human skin surface with an IR beam having components at least in the region of the referencing wavelength and the measuring wavelength, and

c.) detecting and quantifying those referencing and said measuring wavelength components in that reflected IR beam.

5       The procedure ideally includes the further steps of maintaining the skin surface on said ATR plate at an adequate pressure which is both constant and above a selected minimum pressure and, desirably cleaning the skin surface before measurement. A step of actually measuring the pressure may also be included.

10       A normalizing step practiced by simultaneously detecting and quantifying the referencing and measuring wavelength components prior to contacting the skin surface is also desirable.

A final portion of this invention is a cleaning kit used for cleaning the object skin prior to testing. The kit usually is made up of sealed packets, preferably containing absorbent pads, of each of:

15       a.) a glucose solvent, e.g., water or other highly polar solvent,  
b.) a solvent for removing the glucose solvent, e.g., isopropanol, and  
c.) a skin softener or pliability enhancer, e.g., various mineral oils such as "Nujol",  
not having significant IR wavelength peaks between about 8.25 micrometers and about 8.75 micrometers or between about 9.50 micrometers and about 10.00 micrometers. The  
20       solvent for removing the glucose solvent similarly should not have an interfering IR signal which persists after several minutes.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

25       Figures 1A, 1B, 1C, and 1D show a side view of various ATR plates and their general operation.

Figure 2 shows an IR spectrum of d-glucose.

Figure 3 shows a schematicized layout of the optics of the inventive device.

Figure 4 shows a packaged variation of the inventive glucose measuring device.

30       Figure 5 shows a graph correlating glucose levels measured using a specific variation of the device with glucose levels in the blood determined using a commercial device.

Figure 6 shows a pair of glucose IR curves (taken before and after eating) for an individual having diabetes made using the inventive glucose measuring device.

Figure 7 shows a graph comparing glucose levels in a non-diabetic individual (taken before and after eating) made using the inventive glucose measuring device and direct blood measurement. This graph shows that the inventive procedure tracks blood glucose levels with minimum time lag.

### DESCRIPTION OF THE INVENTION

The device in this invention uses infrared ("IR") attenuated total internal reflectance ("ATR") spectroscopy to detect and ultimately to determine the level of blood glucose in the human body. Preferably, the inventive device uses an ATR procedure in which the size and configuration of the crystal permits a number of internal reflections before the beam is allowed to exit the crystal with its measured information. In general, as shown in Figures 1A and 1B, when an infrared beam (102) is incident on the upper surface of the ATR crystal (104) -- or ATR plate -- at an angle which exceeds a critical angle  $\Theta_c$ , the beam (102) will be completely totally reflected within crystal (104). Each reflection of the beam within the ATR plate, and specifically against the upper surface (114), provides a bit more information about the composition of the sample (112) resting against that upper surface (114). The more numerous the reflections, and the greater the penetration depth of the reflection, the higher is the quality of the information. The incident beam (102) becomes reflected beam (106) as it exits crystal (104) as shown in Figure 1A. Higher refractive index materials are typically chosen for the ATR crystal to minimize the critical angle. The critical angle is a function of the refractive indices of both the sample and the ATR crystal and is defined as:

$$\Theta_c = \sin^{-1} \left( \frac{n_2}{n_1} \right)$$

Here,  $n_1$  is the refractive index of the ATR crystal and  $n_2$  is the refractive index of the sample.

As shown in Figure 1B, the internally reflected beam (108) includes an evanescent wave (110) which penetrates a short distance into sample (112) over a wide wavelength

range. In those regions of the IR spectrum in which the sample absorbs IR, some portion of the light does not return to the sensor. It is these regions of IR absorbance which provide information, in this inventive device, for quantification of the glucose level.

We prefer the use of higher refractive crystals such as zinc selenide, zinc sulfide,  
5 diamond, germanium, and silicon as the ATR plate. The index of refraction of the ATR plate (104) should be significantly higher than that of the sample (112).

Further, the ATR crystal (104) shown in Figure 1A is shown to be trapezoidal and having an upper surface (114) for contact with the sample, which sample, in this case, is skin from a living human body. However, this shape is only for the purposes of mechanical  
10 convenience and ease of application into a working commercial device. Other shapes, in particular, a parallelogram (111) such as shown in Figure 1C and the reflective crystal (113) shown in Figure 1D having mirrored end (115), are also quite suitable for this inventive device should the designer so require. The mirrored reflective crystal (113) has the advantage of, and perhaps the detriment of having both an IR source and the IR sensors  
15 at the same end of the crystal.

It is generally essential that the ATR crystal or plate (104) have a sample or upper surface (114) which is essentially parallel to the lower surface (116). In general, the ATR plate (104) is preferably configured and utilized so that the product of the practical number of internal reflections of internal reflected beam (108) and the skin penetration per  
20 reflection of this product is maximized. When maximizing this product, called the effective pathlength (EPL), the information level in beam (106) as it leaves ATR plate (104) is significantly higher. Further, the higher the value of the index of refraction,  $n_2$ , of the ATR plate (104), the higher is the number of internal reflections. The sensitivity of the IR sensors also need not be as high when the EPL is maximized. We consider the number  
25 of total reflections within the crystal to be preferably from 3-15 or more for adequate results.

We have surprisingly found that a glucose measuring device made according to this invention is quite effective on the human skin of the hands and fingers. We have found that the glucose concentration as measured by the inventive devices correlates very closely with  
30 the glucose concentration determined by a direct determination from a blood sample. As will be discussed below, the glucose level as measured by the inventive device also is surprisingly found closely to track the glucose level of blood in time as well. This is



surprising in that the IR beam likely passes into the skin, i.e., the *stratum corneum*, for only a few microns. It is unlikely in a fingertip that any blood is crossed by that light path. The *stratum corneum* is the outer layer of skin and is substantially unvascularized. The *stratum corneum* is the final outer product of epidermal differentiation or keratinization. It is made up of a number of closely packed layers of flattened polyhedral corneocytes (also known as squames). These cells overlap and interlock with neighboring cells by ridges and grooves. In the thin skin of the human body, this layer may be only a few cells deep, but in thicker skin, such as may be found on the toes and feet, it may be more than 50 cells deep. The plasma membrane of the corneocyte appears thickened compared with that of keratinocytes in the lower layers of the skin, but this apparent deposition of a dense marginal band formed by stabilization of a soluble precursor, involucrin, just below the *stratum corneum*.

It is sometimes necessary to clean the skin exterior prior to taking a sample to remove extraneous glucose from the skin surface. When doing so, it is important to select cleaning materials which have IR spectra that do not interfere with the IR spectra of glucose. We consider a kit of the following to be suitable for preparation of the sample skin for the testing. The three components are: a.) a glucose solvent, e.g., water or other highly polar solvent; b.) a solvent for removing the water, e.g., isopropanol, and c.) a skin softener or pliability enhancer not having significant IR peaks in the noted IR regions, e.g., mineral oils such as those sold as "Nujol". Certain mixtures of the first two components may be acceptable, but only if the sampling situation is such that the solvents evaporate without spectrographically significant residue. The inventive kit contains sealed packets of each of the three components, preferably each within an absorbent pad in the sealed packets.

Additionally, the inventive device can be highly simplified compared to other known devices in that the device can be "self-normalizing" due to the specifics of the IR signature of glucose. Figure 2 shows the IR absorbance spectra of d-glucose. The family of curves there shows that in certain regions of the IR spectrum, there is a correlation between absorbance and the concentration of glucose. Further, there is a region in which the absorbance is not at all dependent upon the concentration of glucose. Our device, in its preferable method of use, uses these two regions of the IR spectra. These regions are in the so-called mid-IR range, between 2.5 and 14 micrometers. In particular, the "referencing

wavelength" point is just above 8 micrometers (150), e.g., 8.25 to 8.75 micrometers, and the pronounced peaks (152) at the region between about 9.50 and 10.00 micrometers is used as a "measuring wavelength". The family of peaks (152) may be used to determine the desired glucose concentration.

5           Use of the two noted IR regions is also particularly suitable since other components typically found in the skin, e.g., water, cholesterol, etc., do not cause significant measurement error when using the method described herein.

          Figure 3 shows an optical schematic of a desired variation of the inventive device. ATR crystal (104) with sample side (114) is shown and IR source (160) is provided. IR  
10       source (160) may be any of a variety of different kinds of sources. It may be a broadband IR source, one having radiant temperatures of 300°C to 800°C, or a pair of IR lasers selected for the two regions of measurement discussed above, or other suitably emitted or filtered IR light sources. A single laser is usually not an appropriate light source in that a laser is a single wavelength source and the preferred operation of this device requires light  
15       sources simultaneously emitting two IR wavelengths. Lens (162), for focusing light from IR source (160) into ATR plate (104), is also shown. It may be desirable to include an additional mirror (163) to intercept a portion of the beam before it enters the ATR plate (104) and then to measure the strength of that beam in IR sensor (165). Measurement of that incident light strength (during normalization and during the sample measurement)  
20       assures that any changes in that value can be compensated for.

          The light then passes into ATR plate (104) for contact with body part (164), shown in this instance to be the desired finger. The reflected beam (106) exits ATR plate (104) and is then desirably spit using beam splitter (166). Beam splitter (166) simply transmits some portion of the light through the splitter and reflects the remainder. The two beams  
25       may then be passed through, respectively, lenses (168) and (170). The so-focussed beams are then passed to a pair of sensors which are specifically selected for detecting and measuring the magnitude of the two beams in the selected IR regions. Generally, the sensors will be made up of filter (172) and (174) with light sensors (176) and (178) behind. Generally, one filter (172), (174) will be in the region of the referencing wavelength and  
30       the other will be in that of the measuring wavelength.

          Figure 4 shows perhaps a variation of this device (200) showing the finger of the user (202) over the ATR plate (204) with a display (206). Further shown in this desirable

variation (200) is a pressure maintaining component (208). We have found that is very highly desirable to maintain a minimum threshold pressure on the body part which is to be used as the area to be measured. Generally, a variance in the pressure does not shift the position of the detected IR spectra, but it may affect the sensitivity of the overall device.

5 Although it is possible to teach the user to press hard enough on the device to reach the minimum threshold pressure, we have determined for each design of the device it is much more appropriate that the design of a particular variation of the inventive device be designed with a specific sample pressure in mind. The appropriate pressure will vary with, e.g., the size of the ATR plate and the like. A constant pressure above that minimum  
10 threshold value is most desired.

The variation shown in Figure 4 uses a simple component arm (208) to maintain pressure of the finger (202) on ATR plate (204). Other variations within the scope of this invention may include clamps and the like.

15 It should be apparent that once an appropriate pressure is determined for a specific design, the inventive device may include a pressure sensor, e.g., (210) as is shown in Figure 4, to measure adherence to that minimum pressure. Pressure sensor (210) may alternatively be placed beneath ATR plate (204). It is envisioned that normally a pressure sensor such as (210) would provide an output signal which would provide a "no-go/go" type of signal to the user.

20

#### Method of Use

In general, the inventive device described above is used in the following manner: a skin surface on a human being, for instance, on the skin of the finger, is placed on the ATR plate. The skin surface is radiated with an IR beam having components at least in the two  
25 IR regions we describe above as the "referencing wavelength" and the "measuring wavelength." The beam which ultimately is reflected out of the ATR plate then contains information indicative of the blood glucose level in the user. As noted above, it is also desirable to maintain that skin surface on the ATR plate at a relatively constant pressure that is typically above a selected minimum pressure. This may be done either manually or  
30 by measuring and maintaining the pressure.

Typically, the beam leaving the ATR plate is split using an optical beam splitter into at least two beams. Each of the two beams may be then focussed onto its own IR

sensor. Each such IR sensor has a specific filter. This is to say that, for instance, one IR sensor may have a filter which removes all light which is not in the region of the referencing wavelength and the other IR sensor would have a filter which remove all wavelengths other than those in the region of the measuring wavelength. As noted above,  
 5 for glucose, the referencing wavelength is typically in the range of about 8.25 to 8.75 micrometers. For glucose, the measuring wavelength is typically between about 9.5 and 10.0 micrometers.

Other analyte materials which have both referencing wavelengths and measuring wavelengths in the mid-IR range and that are found in the outer regions of the skin may  
 10 also be measured using the inventive devices and procedures described herein.

Respective signals may be compared using analog or digital computer devices. The signals are then used to calculate blood glucose concentration using various stored calibration values, typically those which are discussed below. The resulting calculated values may then be displayed.

As noted above, it is also desirable both to clean the plate before use and to clean the exterior surface of the skin to be sampled. Again, we have found, for instance in the early morning that the exterior skin is highly loaded with glucose which is easily removed by washing the hands. Reproducible and accurate glucose measurements may then be had in a period as short as ten minutes after cleaning the area of the skin to be measured.

We also note that, depending upon the design of a specific variation of a device made according to the invention, periodic at least an initial calibration of the device, using typical blood sample glucose determinations, may be necessary or desirable.

Determination of blood glucose level from the information provided in the IR spectra is straightforward. A baseline is first determined by measuring the level of infrared absorbance at the measuring and referencing wavelengths, without a sample being present  
 25 on the sample plate. The skin is then placed in contact with the ATR plate and the two specified absorbance values are again measured. Using these four values, the following calculation is then made.

30 
$$A_1 = \ell n \left( \frac{T_{01}}{T_1} \right) = A_{s1} + A_{b1} \quad (\text{Absorbance at referencing spectral band.})$$

$$A_2 = \ln\left(\frac{T_{02}}{T_2}\right) = A_{g2} + A_{b2} \quad (\text{Absorbance at measuring spectral band.})$$

where:  $T_{01}$  = measured value at reference spectral band w/o sample

$T_{02}$  = measured value at measuring spectral band w/o sample

5  $T_1$  = measured value at reference spectral band w/ sample

$T_2$  = measured value at measuring spectral band w/ sample

$A_{g1}$  = absorbance of glucose at reference spectral band

$A_{g2}$  = absorbance of glucose at measuring spectral band

$A_{b1}$  = absorbance of background at reference spectral band

10  $A_{b2}$  = absorbance of background at measuring spectral band

$d$  = effective path length through the sample.

$a_2$  = specific absorptivity at measuring spectral band

$k$  = calibration constant for the device

$C_g$  = measured concentration of glucose

15

Since the background base values are approximately equal (i.e.,  $A_{b1}$   
 $= A_{b2}$ ) and  $A_{g1} = 0$ , then:

20 
$$A_2 - A_1 = A_{g2} = a_2 d c_g = k C_g$$

The value of  $C_g$  is the desired result of this procedure.

### EXAMPLES

25

#### Example 1

Using a commercially available IR spectrometer (Nicolet 510) having a ZnSe crystal ATR plate (55mm long, 10mm wide, and 4mm thick) we tested the inventive

procedure. We calibrated the output of the spectrometer by comparing the IR signal to the values actually measured using one of the inventor's blood samples. The inventor used a blood stick known as "Whisper Soft" sold by Amira Medical Co. and "Glucometer Elite" blood glucose test strips sold by Bayer Corp. of Elkhart, Ind. On each of the various test days, the inventor took several test sticks and measured the glucose value of the resulting blood; the IR test was made at the same approximate time.

As shown in the calibration curve of Figure 5, the data are quite consistent. So, where the blood glucose concentration "B" is in (mg/dl) and "S" is the difference between the absorbance at the referencing region and the measuring region as measured by the spectrometer:

$$B=[(1950) \bullet S]-(17).$$

#### Example 2

In accordance with a clinical protocol, a diabetic was then tested. Curve 1 in Figure 6 shows the IR absorbance spectrum of the test subject's finger before eating (and after fasting overnight) and curve 2 shows IR absorbance spectrum of the same individual after having eaten. Incidentally, insulin was administered shortly after the measurement of curve 2.

In any event, the significant difference in the two peak heights at the 9.75 micrometer wavelength and the equality of the two IR absorbance values at the 8.50 micrometer value shows the effectiveness of the procedure in measuring glucose level.

#### Example 3

That the inventive glucose monitoring device non-invasively determines blood glucose level and quickly follows changes in that blood glucose level is shown in Figure 7. Using both the inventive procedure and a commercial glucose device, one of the inventors followed his glucose level for a single day. The blood sticks are considered to be accurate within 15% of the actual reading.

The results are shown in Figure 7. Of particular interest is the measurement just before 4:40 wherein the two values are essentially the same. A high sugar candy bar was eaten at about 4:45 and measurements of glucose level were taken using the inventive

procedure at about 5:03, 5:18, 5:35 and 5:50. A blood sample was taken at 5:35 and reflected almost the same value as that measured using the inventive procedure. Consequently, the procedure tracks that measured by the blood very quickly.

- 5           This invention has been described and specific examples of the invention have been portrayed. The use of those specifics is not intended to limit the invention in any way. Additionally, to the extent there are variations of the invention which are within the spirit of the disclosure and yet are equivalent to the inventions found in the claims, it is our intent that this patent will cover those variations as well.

**WE CLAIM AS OUR INVENTION:**

1. An analyte level measurement device comprising:
  - a.) an infrared source for emitting an IR beam into an ATR plate, said IR  
5 beam having components at least in the region of a referencing wavelength and a  
measuring wavelength,
  - b.) said ATR plate having a measurement surface for contact with said  
human skin surface and for directing said IR beam against said human skin surface, and
  - c.) at least two IR sensors for simultaneously measuring absorbance of at  
10 least said referencing wavelength and said measuring wavelength.
2. The analyte measurement device of claim 1 wherein said ATR plate is  
configured to permit multiple internal reflections against said measurement surface prior to  
measuring said absorbance.  
15
3. The analyte measurement device of claim 2 wherein said ATR plate is  
configured for 3-15 internal reflections against said measurement surface.
4. The analyte measurement device of claim 1 further comprising a pressure  
20 maintenance member for maintaining adequate pressure of said human skin surface against  
said ATR plate surface.
5. The analyte measurement device of claim 4 wherein said pressure  
maintenance member is configured to maintain a constant and above a selected minimum  
25 pressure of said human skin surface against said ATR plate surface.
6. The analyte measurement device of claim 1 further comprising a pressure  
measurement member situated to measure the pressure of said human skin surface against  
said ATR plate surface.  
30



7. The analyte measurement device of claim 1 wherein said analyte is glucose and said referencing wavelength is between about 8.25 micrometers and about 8.75 micrometers.

5 8. The analyte measurement device of claim 1 wherein said analyte is glucose and said measuring wavelength is between about 9.50 micrometers and about 10.00 micrometers.

10 9. The analyte measurement device of claim 1 further comprising a beam splitter situated between said ATR plate and said at least two IR sensors to form two beams, said two beams for introduction each to one of said at least two IR sensors.

10. The analyte measurement device of claim 1 wherein  
a.) a first of said at least two IR sensors measures said measuring  
15 wavelength and provides a measuring signal related to absorbance of said measuring wavelength, and  
b.) a second of said at least two IR sensors measures said referencing wavelength and provides a referencing signal related to absorbance of said referencing wavelength.

20 11. The analyte measurement device of claim 9 wherein  
a.) a first of said at least two IR sensors measures said measuring wavelength and provides a measuring signal related to absorbance of said measuring wavelength; and  
25 b.) a second of said at least two IR sensors measures said referencing wavelength and provides a referencing signal related to absorbance of said referencing wavelength.

30 12. The analyte measurement device of claim 10 wherein said analyte is glucose and further comprising a comparator for comparing said measuring signal to said referencing signal and providing a signal indicative of blood glucose concentration.

13. The analyte measurement device of claim 10 wherein said analyte is glucose and further comprising a computer component for comparing said measuring signal to said referencing signal and providing a digital signal indicative of blood glucose concentration.

5 14. The analyte measurement device of claim 12 further comprising a display for displaying said blood glucose concentration.

10 15. The analyte measurement device of claim 13 further comprising a display for displaying said blood glucose concentration.

16. The analyte measurement device of claim 1 wherein said infrared source is a broadband source.

15 17. The analyte measurement device of claim 1 wherein said infrared source is a non-laser source.

18. The analyte measurement device of claim 1 wherein said infrared source comprises two selected wavelength lasers.

19. A method for determining the blood glucose level in a human being using a glucose measurement device, comprising the steps of.

a.) contacting a skin surface on said human being with an ATR plate in said glucose measurement device, said ATR plate having a surface for contact with said human skin surface,

b.) irradiating said human skin surface with an IR beam having components at least in the region of a referencing wavelength and a measuring wavelength through said ATR plate to produce a reflected IR beam indicative of the blood glucose level in said human being, and

c.) detecting and quantifying said referencing wavelength and said measuring wavelength components in said reflected IR beam.

20. The method of claim 19 further comprising the step of maintaining said skin surface on said ATR plate at an adequate pressure.

21. The method of claim 19 further comprising the step of maintaining said skin surface on said ATR plate at a constant and above a selected minimum pressure.

22. The method of claim 19 further comprising the step of measuring the pressure of said skin surface on said ATR plate and maintaining said pressure at a relatively constant and above a selected minimum pressure.

23. The method of claim 19 further comprising the step of normalizing the glucose measurement device by simultaneously detecting and quantifying said referencing wavelength and said measuring wavelength components in said reflected IR beam prior to the step of contacting said skin surface on said human being to said ATR plate.

24. The method of claim 19 wherein said referencing wavelength is between about 8.25 micrometers and about 8.75 micrometers.

25. The method of claim 19 wherein said measuring wavelength is between about 9.50 micrometers and about 10.00 micrometers.

26. The method of claim 19 further comprising splitting said reflected beam to form two beams and introducing said two beams each to one of at least two IR sensors.

5           27. The method of claim 19 further comprising the steps of  
a.) measuring the absorbance of said measuring wavelength in a first of said at least two IR sensors and providing a measuring signal related to the absorbance of said measuring wavelength and

10           b.) measuring the absorbance of said referencing wavelength in a second of said at least two IR sensors and providing a referencing signal related to the absorbance of said referencing wavelength.

28. The method of claim 27 further comprising the steps of comparing said measuring signal to said referencing signal and providing a signal indicative of blood  
15 glucose concentration.

29. The method of claim 27 further comprising the steps of comparing said measuring signal to said referencing signal with a digital computer and providing a digital signal indicative of blood glucose concentration.  
20

30. The method of claim 28 further comprising the step of calculating said blood glucose concentration using stored calibration constants.

25           31. The method of claim 29 further comprising the step of calculating said blood glucose concentration using stored calibration constants.

32. The method of claim 30 further comprising the step of displaying said glucose concentration.

30           33. The method of claim 31 further comprising the step of displaying said glucose concentration.

34. The method of claim 19 wherein said irradiating step comprises the step of actuating broadband infrared source.

5 35. The method of claim 19 wherein said irradiating step comprises the step of actuating a non-laser infrared source.

36. The method of claim 19 wherein said irradiating step comprises the step of actuating two selected wavelength lasers.

37. A method for determining the analyte level in a human being using an analyte measurement device, comprising the steps of.

a.) contacting a skin surface on said human being with an ATR plate in said analyte measurement device, said ATR plate having a surface for contact with said human skin surface,

b.) irradiating said human skin surface with an IR beam having components at least in the region of a referencing wavelength and a measuring wavelength through said ATR plate to produce a reflected IR beam indicative of the analyte level in said human being, and

c.) detecting and quantifying said referencing wavelength and said measuring wavelength components in said reflected IR beam.

38. The method of claim 37 further comprising splitting said reflected beam to form two beams and introducing said two beams each to one of at least two IR sensors.

39. The method of claim 38 further comprising the steps of

a.) measuring the absorbance of said measuring wavelength in a first of said at least two IR sensors and providing a measuring signal related to the absorbance of said measuring wavelength and

b.) measuring the absorbance of said referencing wavelength in a second of said at least two IR sensors and providing a referencing signal related to the absorbance of said referencing wavelength.

40. The method of claim 37 further comprising the steps of comparing said measuring signal to said referencing signal and providing a signal indicative of said analyte level.

41. The method of claim 39 further comprising the steps of comparing said measuring signal to said referencing signal with a digital computer and providing a digital signal indicative of said analyte level.

42. The method of claim 40 further comprising the step of calculating said analyte level using stored calibration constants.

5 43. The method of claim 41 further comprising the step of calculating said analyte level using stored calibration constants.

44. The method of claim 42 further comprising the step of displaying said analyte level.

10 45. The method of claim 43 further comprising the step of displaying said analyte level.

46. The method of claim 37 wherein said irradiating step comprises the step of actuating broadband infrared source.

15

47. The method of claim 37 wherein said irradiating step comprises the step of actuating a non-laser infrared source.

20 48. The method of claim 37 wherein said irradiating step comprises the step of actuating two selected wavelength lasers.

49. A cleaning kit comprising sealed packets of each of:  
a.) a glucose solvent,  
b.) a solvent for removing the glucose solvent, and  
c.) a skin softener or pliability enhancer not having significant IR wavelength peaks  
5 between about 8.25 micrometers and about 8.75 micrometers or between about 9.50  
micrometers and about 10.00 micrometers.

50. The cleaning kit of claim 49 wherein each of said glucose solvent, solvent  
for removing the glucose solvent, and skin softener or pliability enhancer are present in an  
10 absorbent pad within said sealed packets.

51. The cleaning kit of claim 49 wherein the glucose solvent comprises water or  
other highly polar solvent.

15 52. The cleaning kit of claim 49 wherein the solvent for removing the glucose  
solvent comprises isopropanol.

53. The cleaning kit of claim 49 wherein the skin softener or pliability enhancer  
comprises a mineral oil.  
20



1/7




FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D

2/7




FIG. 2

3/7




FIG. 3

4/7




FIG. 4

5/7




FIG. 5

6/7




FIG. 6

7/7




FIG. 7